- Open Access
Evaluation of lipoprotein-associated Phospholipase A2 in Healthy Chinese Han Adult Serum
© Feng et al.; licensee BioMed Central Ltd. 2014
- Received: 7 November 2013
- Accepted: 3 January 2014
- Published: 7 January 2014
The aim of this study is to establish lipoprotein-associated phospholipase A2 (Lp-PLA2) reference intervals (RIs) in healthy Chinese Han adults as a clinical diagnostic indicator according to the Clinical and Laboratory Standards Institute (CLSI) C28-A3 guidelines.
Design and methods
Lp-PLA2 levels in 763 healthy Chinese Han subjects (392 males and 371 females) were determined by colorimetric analysis and the central 95th percentile RIs were determined using non-parametric statistical methods. The correlations between serum Lp-PLA2 and blood markers were analyzed by Spearman correlation analyses.
The Lp-PLA2 levels showed a Gaussian distribution with a statistically significant difference between females and males (t = 4.866, P < 0.001). The RIs of serum Lp-PLA2 were 194–640 U/L (18–49 years) and 208–698 U/L (50–88 years) for females, and 230–728 U/L for males. There was a positive correlation between Lp-PLA2 levels and age, Body Mass Index (BMI), as well as with levels of alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), total bilirubin (TBIL), triglyceride (TG), total cholesterol (Tch), low density lipoprotein cholesterol (LDL-c), apolipoprotein B (apoB), glucose (Glu), high sensitivity C reactive protein (Hs-CRP), white blood cell (WBC), hemoglobin (HGB) and red blood cell (RBC) (P < 0.05). A negative correlation was found with high density lipoprotein cholesterol (HDL-c) and Apolipoprotein AI (apoAI), and no correlation was found with platelet (Plt) levels.
Our results establish the RIs of serum Lp-PLA2 in healthy Chinese Han adults and demonstrate correlations between serum Lp-PLA2 and age, BMI, ALT, GGT, TBIL, TG, Tch, HDL-c, LDL-c, apoAI, apoB, Glu, Hs-CRP, WBC, RBC, and HGB levels.
- Lipoprotein-associated phospholipase A2 (Lp-PLA2)
- Chinese Han adult
- Reference interval
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as plasma platelet-activating factor acetylhydrolase (PAF-AH), is a Ca2+-independent enzyme and a member of the phospholipase A2 superfamily . Lp-PLA2 hydrolyzes platelet-activating factor (PAF) and oxidizes phospholipids with a modified short fatty acyl chain esterified at the Sn-2 position . Many studies have indicated that Lp-PLA2 is an independent predictor for cardiovascular disease (CAD), with elevated Lp-PLA2 activity associated with an increased risk for CAD [3–5]. Additionally, Lp-PLA2 levels have been implicated in atherosclerotic plaque formation , inflammatory bowel disease , acute respiratory distress syndrome  and severe anaphylaxis .
Brilakis et al.  revealed that Lp-PLA2 activity and mass are independently influenced by race and gender. The largest ethnic group both in China and the world is the Chinese Han, and therefore related studies investigating the activity distribution of Lp-PLA2 in this population will be of great significance and pave the way for clinical diagnosis and study. Reference intervals of Lp-PLA2 levels are an important parameter for the clinical evaluation of patient health. To the best of our knowledge, there have been no relevant published studies defining Lp-PLA2 reference intervals (RIs) in the Han population of China. This study establishes the RIs according to the recommendations of the CLSI C28-A3 document and evaluates the correlations between serum Lp-PLA2 and blood markers in healthy Han adults .
In this study, 763 adults of Han ethnicity from Zhejiang province in Eastern China who were attending their annual health examination in the healthcare center of the First Affiliated Hospital of Zhejiang University were recruited as subjects. The health status of these participants was determined by a self-report questionnaire. Of the 763 subjects, 392 were males between the ages of 18–87 years (mean: 57.4 years) and 371 were females between 18–88 years (mean: 53.0 years). All participants met the following requirements: no history of cardiovascular disease or diabetes mellitus, not taking lipid-lowering drugs, not taking corticosteroids, triglyceride level below 1.70 mmol/L, total cholesterol level below 5.70 mmol/L, low density lipoprotein cholesterol (LDL-c) level below 3.61 mmol/L, high density lipoprotein cholesterol (HDL-c) above 0.91 mmol/L, fasting blood glucose level below 6.16 mmol/L and normal liver and kidney function. The standards above, excluding populations manifesting abnormal blood lipids that are an important risk factor for atherosclerotic cardiovascular disease, are outlined in the ‘Guidelines on Prevention and Treatment of Blood Lipid Abnormality’ established by the Special Group on Prevention and Treatment of Blood Lipid Abnormality affiliated with the Chinese Journal of Cardiology . This study was approved by the Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University, and written informed consent was obtained from each individual.
Venous blood was collected from subjects in a state of quiet and fasting. Serum samples were obtained by centrifugation within 2 hours of initial collection, and stored at - 80°C for processing. Routine analyses of blood samples were completed on the same day.
Serum samples were tested using a Hitachi 7600 automatic biochemical analyzer (Hitachi Ltd., Tokyo, Japan) equipped with an Azwell Auto PAF-AH kit (Azwell Inc., Osaka, Japan). According to colorimetry methods previously reported by Kosaka et al., the activity of Lp-PLA2 was detected based on the principle that it catalytically hydrolyzes the Sn-2 position of the substrate 1-myristoyl-2-(4-nitrophenylsuccinyl) phosphatidylcholine and produces 4-nitrophenyl succinate which is immediately degraded to 4-nitrophenol in an aqueous solution, which can be detected at an absorbance reading of 405 nm.
Biochemical and blood cell count assays
Alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), total bilirubin (TBIL), triglyceride (TG), total cholesterol (Tch), high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c), apolipoprotein AI (ApoAI), apolipoprotein B (apoB), glucose (Glu), and high sensitivity C reactive protein (Hs-CRP) levels were measured with a Hitachi 7600 automatic biochemical analyzer using Roche reagents (Roche Diagnostics, Mannheim, Germany) for ALT, GGT, TBIL, TG, Tch and Glu, and using SSUF reagents (SSUF, Shanghai, China) for Hs-CRP, LDL-c, HDL-c, apoAI and apoB. White blood cell (WBC), red blood cell (RBC), and platelet (Plt) levels were measured using the XE-2100 automated hematology analyzer (Sysmex, Kobe, Japan) with Sysmex reagents (Sysmex, Kobe, Japan).
All the experimental data was statistically analyzed using SPSS 13.0 software. The reference intervals acquired are expressed as medians and percentiles. Statistical methods recommended by the CLSI C28-A3 document were used to define the RIs . The recommended nonparametric central 95th percentile intervals were used to define the RIs for their simplicity and reliability . One-sample Kolmogorov-Smirnov tests were used for assessing normality of Lp-PLA2 level distributions and one-way analyses of variance (ANOVA) were used for comparisons across different groups. Outliers in the selected data were detected by means of the Dixon outlier range statistic [11, 14]. For comparison between gender groups, Student’s t-tests were used, and Spearman correlation analyses were applied for correlations between serum Lp-PLA2 and other blood markers in the whole study population. As an index to estimate the extent of obesity, the body-mass index (BMI) was calculated by body weight (kg) divided by the square of the height (m2). For all analyses, a P value below 0.05 indicated statistical significance.
Assessment of distribution normality
Main characteristics of 763 healthy Chinese Han participants
55.3 ± 15.1
22.6 ± 3.0
18.6 ± 8.7
23.2 ± 11.0
13.2 ± 4.9
1.07 ± 0.41
4.21 ± 0.64
1.31 ± 0.32
2.44 ± 0.52
1.19 ± 0.28
0.72 ± 0.16
fasting glucose (mmol/L)
4.79 ± 0.55
5.84 ± 1.47
136.6 ± 23.1
4.42 ± 0.76
202 ± 59
1.7 ± 3.9
Lp-PLA2 activity (U/L)
467 ± 127
Serum RIs of Lp-PLA2 based on gender and Age
RIs of serum Lp-PLA2 levels (U/L) in healthy Chinese Han adults
Percentile of reference interval
Correlation between Lp-PLA2 and other blood markers
Spearman correlation coefficients between serum Lp-PLA2 and blood markers
This study establishes the RIs of serum Lp-PLA2 levels in healthy Chinese Han participants according to the CLSI C28-A3 guidelines . Furthermore, sample sizes used in this study are in accordance with the guidelines, which recommend a minimum of 120 subjects for each partition group . This study demonstrates gender differences in RIs of serum Lp-PLA2 levels, with, significantly lower serum levels in females as compared to males (230–728 U/L), as well as a female age difference, with females 18–49 years of age showing lower levels those of females 50–88 years of age (194–640 and 208–698 U/L, respectively). These results are in agreement with previous studies reporting lower Lp-PLA2 activity levels in female as compared to male [15, 16]. Kosaka et al. reported the serum Lp-PLA2 activity for females was significantly lower than that of males at the 5% level in a healthy Japanese population, and suggested that Lp-PLA2 activity levels were inversely proportional to estrogen concentrations, with Lp-PLA2 activity levels in females ≥ 50 years higher than in younger females, similar to the results of this study.
The median levels of Lp-PLA2 in males and females in this study were 504 U/L and 446 U/L, respectively, which were similar to the values (male, 506 U/L; female, 439 U/L) previously reported by Winkler et al.. The low Lp-PLA2 levels observed in females may result from the secretion of estrogen, as Lp-PLA2 levels in pre-menopausal females were lower than those of menopausal females. This estrogen effect was suggested in a study by Yoshimura et al. showing a 26% reduction in Lp-PLA2 levels in menopausal females two weeks after receiving estrogen replacement therapy.
Lp-PLA2 is an enzyme that mainly exists in combination with lipoprotein particles in blood circulation, with 80-85% bound to LDL, approximately 15-20% bound to HDL . Da Silva et al. analyzed the influence of obesity on Lp-PLA2 and found that enzyme activity was positively associated with BMI and the function of Lp-PLA2 changes with adolescent obesity . A positive correlation also had been established between Lp-PLA2 levels and Tch, LDL-c and apoB, and a negative correlation with HDL-c and apoA I, which was confirmed by the results of this study. These data suggest that Lp-PLA2 is present in atherogenic lipoproteins. Similarly, the confirmation of a positive correlation with ALT, GGT and TBIL can be associated with the secretion of Lp-PLA2 from liver cells , which may be the principal source of biliary Lp-PLA2 responsible for the adjustment of gastrointestinal PAF and phospholipid metabolism . Stafforini et al. found that apoB was the factor most strongly correlated with Lp-PLA2 levels, which manifests a strong bonding force with Lp-PLA2 due to its carboxyl terminus . ApoB is a structural protein of lipoproteins, excluding HDL-c, and plays an important role in transporting lipids to extrahepatic tissues and recognizing LDL receptors. Some studies indicated that Lp-PLA2 induced WBC activation and inflammatory responses in vitro, and that this activation may be associated with a rapid increase in circulatory Lp-PLA2 expression [24, 25]. Yoshida et al. found that Lp-PLA2 may play an important role in scavenging oxidized phospholipids in RBC membranes and in maintaining the normal rheological properties of erythrocytes . Furthermore, Uydu et al. reported that serum Lp-PLA2 was positively associated with the variations of Hs-CRP in stable CAD patients and was a more reliable indicator of coronary stenosis . These findings may help explain the positive correlations observed between Lp-PLA2 levels and Hs-CRP, HGB, WBC, and RBC in this study. Taken together, the data suggest that after Lp-PLA2 is bound to LDL via apoB, lysophosphatidylcholine and free oxidized fatty acids, two strong pro-inflammatory factors, are produced through the hydrolysis and oxidation of phospholipids, thereby promoting chronic inflammation and atherosclerosis .
Lp-PLA2 has recently attracted considerable attention for its importance in predicting cardiovascular disease and prognostic evaluation. In addition, Lp-PLA2 has also been proposed as a new independent risk factor for the development and progression of coronary heart disease [29, 30]. As a result, the establishment of a reference interval for Lp-PLA2 levels is needed for the clinical evaluation of patients with cardiovascular disease. Moreover, considering the influence of gender and age on Lp-PLA2 levels, our results not only provide an alternative reference for clinical practice, but also pave the way for further clinical studies.
This work was financially supported by grants from the Department of Education Foundation of Zhejiang Province, China (Y201330146).
Role of funding source
The funding organization had no role in the design or conduct of this research.
- Dennis EA: The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci. 1997, 22 (1): 1-2. 10.1016/S0968-0004(96)20031-3View ArticlePubMedGoogle Scholar
- Arai H: Platelet-activating factor acetylhydrolase. Prostaglandins Other Lipid Mediat. 2002, 68–69: 83-94.View ArticlePubMedGoogle Scholar
- Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005, 111 (5): 570-575. 10.1161/01.CIR.0000154553.12214.CDView ArticlePubMedGoogle Scholar
- Kim JY, Hyun YJ, Jang Y, Lee BK, Chae JS, Kim SE, Yeo HY, Jeong TS, Jeon DW, Lee JH: Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case–control study. Am J Clin Nutr. 2008, 88 (3): 630-637.PubMedGoogle Scholar
- Anuurad E, Ozturk Z, Enkhmaa B, Pearson TA, Berglund L: Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. J Clin Endocrinol Metab. 2010, 95 (5): 2376-2383. 10.1210/jc.2009-2498PubMed CentralView ArticlePubMedGoogle Scholar
- Goncalves I, Edsfeldt A, Ko NY, Grufman H, Berg K, Bjorkbacka H, Nitulescu M, Persson A, Nilsson M, Prehn C: Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol. 2012, 32 (6): 1505-1512. 10.1161/ATVBAHA.112.249854View ArticlePubMedGoogle Scholar
- Oshimoto H, Okamura S, Iida T, Ishikawa T, Hosaka K, Mori M: Diagnostic value of the serum platelet-activating factor acetylhydrolase activity in inflammatory bowel disease. Tohoku J Exp Med. 2005, 207 (1): 65-71. 10.1620/tjem.207.65View ArticlePubMedGoogle Scholar
- Nakos G, Kitsiouli E, Hatzidaki E, Koulouras V, Touqui L, Lekka ME: Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med. 2005, 33 (4): 772-779. 10.1097/01.CCM.0000158519.80090.74View ArticlePubMedGoogle Scholar
- Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, Simons FE, Simons KJ, Cass D, Yeung J: Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. 2008, 358 (1): 28-35. 10.1056/NEJMoa070030View ArticlePubMedGoogle Scholar
- Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, de Lemos JA: Influence of race and gender on lipoprotein-associated phospholipase A2 levels: observations from the dallas heart study. Atherosclerosis. 2008, 199 (1): 110-115. 10.1016/j.atherosclerosis.2007.10.010PubMed CentralView ArticlePubMedGoogle Scholar
- Horowitz GL, Altaie S, Boyd JC, Ceriotti F, Garg U, Horn P, Pesce A, Sine HE, Zakowski J, : Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory. [Approved Guideline], Volume 28. 2008, 1-61. Clinical Laboratory and Standards Institute, 3,Google Scholar
- Fang Q, ZW , Ning TH, Shao G, Chen ZJ, Lu ZL, Li JZ, Lin CX, Zhou BF, Zhu JR, Hu YK, Tao P, Tao SQ, Gong LS, Gu FS, You K, Dai YH: Guidelines on prevention and treatment of blood lipid abnormality. Chinese Journal of Cardiology. 1997, 25: 169-175.Google Scholar
- Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, Toyosato M, Mizuno K: Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta. 2000, 296 (1–2): 151-161.View ArticlePubMedGoogle Scholar
- Horn PS, Feng L, Li Y, Pesce AJ: Effect of outliers and nonhealthy individuals on reference interval estimation. Clin Chem. 2001, 47 (12): 2137-2145.PubMedGoogle Scholar
- Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, McConnell JP: Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol. 2006, 9 (3): 138-143. 10.1111/j.1520-037X.2006.05547.xView ArticlePubMedGoogle Scholar
- Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Bohm BO, Marz W: Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation. 2005, 111 (8): 980-987. 10.1161/01.CIR.0000156457.35971.C8View ArticlePubMedGoogle Scholar
- Kosaka T, Yamaguchi M, Miyanaga K, Mizuno K: Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese. Clin Chim Acta. 2001, 312 (1–2): 179-183.View ArticlePubMedGoogle Scholar
- Yoshimura T, Ohshige A, Maeda T, Ito M, Okamura H: Estrogen replacement therapy decreases platelet-activating factor-acetylhydrolase activity in post-menopausal women. Maturitas. 1999, 31 (3): 249-253. 10.1016/S0378-5122(99)00004-3View ArticlePubMedGoogle Scholar
- Silva IT, Mello AP, Damasceno NR: Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2): a review. Lipids Health Dis. 2011, 10: 170- 10.1186/1476-511X-10-170PubMed CentralView ArticlePubMedGoogle Scholar
- Da Silva IT, Timm Ade S, Damasceno NR: Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study. Lipids Health Dis. 2013, 12: 19- 10.1186/1476-511X-12-19PubMed CentralView ArticlePubMedGoogle Scholar
- Tarbet EB, Stafforini DM, Elstad MR, Zimmerman GA, McIntyre TM, Prescott SM: Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase. J Biol Chem. 1991, 266 (25): 16667-16673.PubMedGoogle Scholar
- Svetlov SI, Howard KM, Debuysere MS, Olson MS: Secretory PAF-acetylhydrolase of the rat hepatobiliary system: characterization and partial purification. Am J Physiol. 1998, 274 (5 Pt 1): G891-G900.PubMedGoogle Scholar
- Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM: Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem. 1999, 274 (11): 7018-7024. 10.1074/jbc.274.11.7018View ArticlePubMedGoogle Scholar
- Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M, Ikeda Y, Yamaguchi K: Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999, 261 (2): 511-514. 10.1006/bbrc.1999.1066View ArticlePubMedGoogle Scholar
- Shi Y, Zhang P, Zhang L, Osman H, Mohler ER, Macphee C, Zalewski A, Postle A, Wilensky RL: Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis. 2007, 191 (1): 54-62. 10.1016/j.atherosclerosis.2006.05.001View ArticlePubMedGoogle Scholar
- Yoshida H, Satoh K, Takamatsu S: Platelet-activating factor acetylhydrolase in red cell membranes. Does decreased activity impair erythrocyte deformability in ischemic stroke patients?. Stroke. 1993, 24 (1): 14-18. 10.1161/01.STR.24.1.14View ArticlePubMedGoogle Scholar
- Uydu HA, Bostan M, Yilmaz A, Demir A, Atak M, Satiroglu Ö, Temiz A, Cicek Y, Erdogan T, Cetin M, Canga A: Comparision of inflammatory biomarkers for detection of coronary stenosis in patients with stable coronary artery disease. Eur Rev Med Pharmacol Sci. 2013, 17 (1): 112-118.PubMedGoogle Scholar
- Benitez S, Camacho M, Arcelus R, Vila L, Bancells C, Ordonez-Llanos J, Sanchez-Quesada JL: Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL. Atherosclerosis. 2004, 177 (2): 299-305.PubMedGoogle Scholar
- Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000, 343 (16): 1148-1155. 10.1056/NEJM200010193431603View ArticlePubMedGoogle Scholar
- May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, Clarke JL, Kolek MJ, Bair TL, Pearson RR: Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J. 2006, 152 (5): 997-1003. 10.1016/j.ahj.2006.01.011View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.